• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Scorpius Holdings Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Entry into a Material Definitive Agreement, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8/9/24 5:05:44 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SCPX alert in real time by email
    false 0001476963 0001476963 2024-08-06 2024-08-06 0001476963 us-gaap:CommonStockMember 2024-08-06 2024-08-06 0001476963 SCPX:CommonStockPurchaseRightsMember 2024-08-06 2024-08-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (date of earliest event reported): August 6, 2024

     

    Scorpius Holdings, Inc.

    (Exact name of registrant as specified in charter)

     

    Delaware

    (State or other jurisdiction of incorporation)

     

    001-35994 26-2844103
    (Commission File Number) (IRS Employer Identification No.)

     

    627 Davis Drive, Suite 300

    Morrisville, North Carolina 27560

    (Address of principal executive offices and zip code)

     

    (919) 240-7133

    (Registrant’s telephone number including area code)

     

     

    (Former Name and Former Address)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

     

      ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

      ¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)

     

      ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

      ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

     

    Title of each class Trading Symbol(s) Name of each exchange on which registered
    Common Stock, $0.0002 par value per share SCPX NYSE American LLC
    Common Stock Purchase Rights None NYSE American LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company  ¨  

     

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     
     
     
     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On August 6, 2024, Scorpius Holdings, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with ThinkEquity LLC (the “ThinkEquity”), as representative of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell to the several Underwriters in a firm commitment public offering (the “Offering”) 12,500,000 shares (the “Shares”) of the Company’s common stock, par value $0.002 per share (the “Common Stock”), or pre-funded warrants (the “Pre-Funded Warrants”) to purchase shares of Common Stock (the “Pre-Funded Warrant Shares”) in lieu thereof, at a purchase price of $0.93 per Share and $0.929814 per Pre-Funded Warrant (93% of the public offering price per Share or Pre-Funded Warrant).

     

    On August 7, 2024, ThinkEquity provided the Company with a notice of termination of the Underwriting Agreement based on the suspension of the trading in the Company’s Common Stock on the NYSE American, LLC (“NYSE American”), and as result of the unexpected decision by the staff of the NYSE American with respect to its treatment of the announced public Offering by the Company.

     

    The Shares, the Pre-Funded Warrants and the Pre-Funded Warrant Shares (collectively referred to as the “Securities”) are being offered by the Company pursuant to the Company’s Registration Statement on Form S-1 (File No. 333-280887), as amended to date, filed by the Company with the Securities and Exchange Commission (the “SEC”) under the Securities Act of 1933, as amended (the “Securities Act”), that became effective on August 6, 2024. A new underwriting agreement will be entered into if a subsequent offering is consummated and the closing of the Offering is expected to occur on or about August 19, 2024. Trading of the Company’s Common Stock was halted by NYSE American as of August 7, 2024.

     

    The foregoing does not purport to be a complete description of the Underwriting Agreement and is qualified in its entirety by reference to the full text of such document, which is filed as Exhibit 1.1 to this Current Report on Form 8-K and is incorporated herein by reference.

    Item 1.02 Termination of Material Definitive Agreement

    The information contained in Item 1.01 is incorporated herein by reference.

    Item 7.01 Regulation FD Disclosure.

     

    On August 9, 2024, the Company issued a press release announcing that Company has requested, and the NYSE American has approved, a financial viability exception to the NYSE American stockholder approval rules that would allow it to proceed with the closing of an underwritten public offering. The Company intends to pursue the sale of 12,500,000 shares of common stock (or Pre-Funded Warrants in lieu thereof), exclusive of the over-allotment option, at a price of $1.00 per share (inclusive of the Pre-Funded Warrant exercise price). The Underwriting Agreement was terminated in connection with the Offering and a new underwriting agreement will be entered into if the offering is consummated. There can be no assurance that the Company will be able to consummate an offering under these terms or otherwise. The Company will adhere to all applicable provisions relating to the exemption, as outlined in Section 710 of the NYSE American Company Guide, and a closing is intended to occur ten days following the mailing of a notification letter to the Company’s stockholders.

    The Audit Committee of the Company’s Board of Directors (the “Board”), composed solely of independent and disinterested members of the Board, determined that the delay associated with obtaining a stockholder vote prior to consummation of the Offering and the issuance of the Securities would seriously jeopardize the financial viability of the Company, and, on that basis, the Audit Committee expressly approved the Company’s reliance on the financial viability exception to the requirement to seek stockholder approval. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.

    In accordance with NYSE American requirements, the Company will mail a letter to stockholders, not later than ten days prior to the anticipated closing of the issuance of the Securities, notifying them of its agreement with ThinkEquity, pursuant to an underwriting agreement, to, among other things, issue the Securities upon consummation of the Offering, without obtaining approval from its stockholders (the “Stockholder Letter”). A copy of the Stockholder Letter to be mailed is attached as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated by reference into this Item 7.01.

    The information under this Item 7.01, including Exhibit 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act or the Exchange Act.

     
     

    Item 8.01. Other Events

     

    On August 9, 2024, the Company issued a press release announcing that Company has requested, and the NYSE American has approved, a financial viability exception to the NYSE American stockholder approval rules that would allow it to proceed with the closing of an underwritten public offering. The Company intends to pursue the sale of 12,500,000 shares of common stock (or Pre-Funded Warrants in lieu thereof), exclusive of the over-allotment option, at a price of $1.00 per share (inclusive of the Pre-Funded Warrant exercise price). The Underwriting Agreement was terminated in connection with the Offering and a new underwriting agreement will be entered into if the offering is consummated. There can be no assurance that the Company will be able to consummate an offering under these terms or otherwise. The Company will adhere to all applicable provisions relating to the exemption, as outlined in Section 710 of the NYSE American Company Guide, and a closing is intended to occur ten days following the mailing of a notification letter to the Company’s stockholders.

    Item 9.01 Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit
    Number
      Exhibit Description
    1.1   Form of Underwriting Agreement (incorporated by reference to Exhibit 1.2 to the Registration Statement on Form S-1/A filed with the Securities and Exchange Commission on August 1, 2024 (333-280887))
    99.1   Press Release, dated August 9, 2024
    99.2   Stockholder Letter, dated August 9, 2024
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

     

     

     

     
     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated:  August 9, 2024 SCORPIUS HOLDINGS, INC.
       
         
      By: /s/ Jeffrey Wolf
      Name: Jeffrey Wolf
      Title:

    Chairman, President and

    Chief Executive Officer

     

     

     

    Get the next $SCPX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SCPX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SCPX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tivic Health Enters GMP Manufacturing Validation Agreement with Scorpius BioManufacturing in Preparation for FDA Submission

    Tivic Health® Systems, Inc. (NASDAQ:TIVC), a diversified therapeutics company, announced today it has entered a definitive agreement with Scorpius BioManufacturing to complete the GMP manufacturing validation of the lead candidate from its TLR5 program, Entolimod™, for treatment of Acute Radiation Syndrome, or ARS, in preparation for filing a Biological Licensing application, or BLA, with the U.S. Food & Drug Administration. Scorpius BioManufacturing, Inc. is an integrated contract development and manufacturing organization (CDMO) and subsidiary of Scorpius Holdings Inc. (OTC:SCPX), which will be the primary U.S. manufacturer for Entolimod™. Scorpius plans to utilize its scientific and tec

    5/14/25 8:30:00 AM ET
    $SCPX
    $TIVC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia

    Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX , May 05, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC:SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a corporate update highlighting key strategic initiatives, including cost optimization measures expected to yield over $6 million in annualized savings and the Company's exploration of opportunities to expand operations into Southeast Asia through a potential biomanufacturing presence in Malaysia. Major Operational Cost Optimization Progr

    5/5/25 8:00:00 AM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scorpius Holdings Provides 2024 Year-End Business Update; Implements Strategic Cost Reductions and Operational Streamlining

    SAN ANTONIO, April 30, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided strategic, financial, and operational updates for the year ended December 31, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "The current biotech funding environment has created real headwinds for many of our clients, particularly when it comes to advancing drug development and clinical trials. In response, we took decisive steps to streamline our operations, reduce our cost structure, and refocus on our core CDMO capabilities. While the delay in our Form 10-K filing was not id

    4/30/25 4:05:30 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Thuan Tan Sze

    3 - Scorpius Holdings, Inc. (0001476963) (Issuer)

    3/12/25 4:07:02 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolf Jeffrey Alan was granted 2,500,000 shares (SEC Form 4)

    4 - Scorpius Holdings, Inc. (0001476963) (Issuer)

    5/17/24 4:30:21 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPX
    SEC Filings

    View All

    Amendment: Scorpius Holdings Inc. filed SEC Form 8-K: Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets, Events That Accelerate or Increase a Direct Financial Obligation

    8-K/A - Scorpius Holdings, Inc. (0001476963) (Filer)

    3/10/26 4:15:26 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Scorpius Holdings Inc.

    10-Q - Scorpius Holdings, Inc. (0001476963) (Filer)

    2/17/26 4:35:40 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scorpius Holdings Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits, Events That Accelerate or Increase a Direct Financial Obligation

    8-K - Scorpius Holdings, Inc. (0001476963) (Filer)

    1/29/26 4:15:42 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPX
    Leadership Updates

    Live Leadership Updates

    View All

    Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia

    Operational Realignment Expected to Deliver Over $6 Million in Annual Cost Savings Company Exploring CDMO Expansion Opportunities in Southeast Asia San Antonio, TX , May 05, 2025 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (OTC:SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a corporate update highlighting key strategic initiatives, including cost optimization measures expected to yield over $6 million in annualized savings and the Company's exploration of opportunities to expand operations into Southeast Asia through a potential biomanufacturing presence in Malaysia. Major Operational Cost Optimization Progr

    5/5/25 8:00:00 AM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scorpius Holdings Reports Third Quarter 2024 Results, Highlighting Strategic Partnerships, Cost Savings, and Progress Toward Profitability

    DURHAM, N.C., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today provided a strategic, financial, and operational update for the third quarter ended September 30, 2024. Jeff Wolf, CEO of Scorpius Holdings, Inc., stated, "Scorpius continued to make strides in Q3, driven by key partnerships, disciplined financial management, and growth across our manufacturing and development services. We are proud to report a 142% year-over-year increase in revenue for the nine months ended September 30, 2024, reaching $5.2 million, which illustrates the demand fo

    11/14/24 4:15:00 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Scorpius Holdings Selected to Join Medical CBRN Defense Consortium to Advance Medical Countermeasures Against Chemical, Biological, Radiological, and Nuclear Threats

    DURHAM, N.C., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) ("Scorpius" or "the Company"), an integrated contract development and manufacturing organization ("CDMO"), today announced that it has been selected to join the Medical CBRN Defense Consortium (MCDC), a key organization advancing the development of medical countermeasures and related technologies to protect U.S. military personnel and civilians from chemical, biological, radiological, and nuclear (CBRN) threats. The MCDC, established in 2015 under the U.S. Department of Defense (DoD), serves as a collaborative framework for government, industry, and academia to partner on cutting-edge medical solu

    10/2/24 8:00:00 AM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SCPX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Scorpius Holdings Inc.

    SC 13G - Scorpius Holdings, Inc. (0001476963) (Subject)

    9/26/24 4:05:52 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Scorpius Holdings Inc.

    SC 13G - Scorpius Holdings, Inc. (0001476963) (Subject)

    9/6/24 4:01:41 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Scorpius Holdings Inc. (Amendment)

    SC 13D/A - Scorpius Holdings, Inc. (0001476963) (Subject)

    5/21/24 5:25:39 PM ET
    $SCPX
    Biotechnology: Pharmaceutical Preparations
    Health Care